Beamion LUNG-1 And LUNG-2: The Zongertinib Clinical Program in Patients with Non-Small Cell Lung Cancer and HER2 Mutations

被引：0

作者：

Wu, Y. -L. ^{[1
]}

Opdam, F. ^{[2
]}

Yamamoto, N. ^{[3
]}

Yoshida, T. ^{[3
]}

Heymach, J. ^{[4
]}

机构：

[1] Southern Med Univ, Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China

[2] Netherlands Canc Inst, Amsterdam, Netherlands

[3] Natl Canc Ctr, Chuo Ku, Tokyo, Japan

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.12D.06

引用

页码：S348 / S348

页数：1

共 50 条

[21] HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies
Uy, Natalie F.
Merkhofer, Cristina M.
Baik, Christina S.
CANCERS, 2022, 14 (17)
[22] The Prognostic Significance of HER2 Overexpression in Non-small Cell Lung Cancer
Takenaka, Masaru
Hanagiri, Takeshi
Shinohara, Shinji
Kuwata, Taiji
Chikaishi, Yasuhiro
Oka, Soich
Shigematsu, Yoshiki
Nagata, Yoshika
Shimokawa, Hidehiko
Nakagawa, Makoto
Uramoto, Hidetaka
So, Tomoko
Tanaka, Fumihiro
ANTICANCER RESEARCH, 2011, 31 (12) : 4631 - 4636
[23] Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib
Liu, Shengwu
Li, Shuai
Hai, Josephine
Wang, Xiaoen
Chen, Ting
Quinn, Max M.
Gao, Peng
Zhang, Yanxi
Ji, Hongbin
Cross, Darren A. E.
Wong, Kwok-Kin
CLINICAL CANCER RESEARCH, 2018, 24 (11) : 2594 - 2604
[24] Targeting HER2 genomic alterations in non-small cell lung cancer
Zeng, Jie
Ma, Weijie
Young, Richard Benjamin
Li, Tianhong
JOURNAL OF THE NATIONAL CANCER CENTER, 2021, 1 (02): : 58 - 73
[25] Beamion LUNG-1, a phase Ia/Ib trial of the HER2-specific tyrosine kinase inhibitor, zongertinib (BI 1810631), in patients with HER2driven tumours: outcomes according to HER2 aberration type in lung and other tumours
Feuersinger, A.
Opdam, F.
Heymach, J.
Barve, M.
Tu, H.
Wu, Y.
Berz, D.
Mueller, A. M.
von Wangenheim, U.
Serra, J.
Yoh, K.
Yamamoto, N.
VIRCHOWS ARCHIV, 2024, 485 : S425 - S426
[26] Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having HER2 alterations
Xiaoli Zhuo
Honglin Guo
Jun Ma
Jingjiang Lai
Lei Liu
Ke Yin
Jing Zhao
Jingliang Wang
Fengxian Jiang
Wei Xu
Xiaotian Yuan
Xiaoyan Lin
Guobin Fu
Journal of Cancer Research and Clinical Oncology, 2023, 149 : 2029 - 2039
[27] Characteristics and predictive modeling of HER2 mutation in patients with non-small cell lung cancer
Varolgunes, Uras
Mittal, Garima
Parikh, Kaushal
Ip, Andrew
Malhotra, Jyoti
Bates, Benjamin
Salas, Maribel
Arunachalam, Meena
Chen, Haoqian
Chen, Wenjin
Yu, Dantong
Setoguchi, Soko
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[28] Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having HER2 alterations
Zhuo, Xiaoli
Guo, Honglin
Ma, Jun
Lai, Jingjiang
Liu, Lei
Yin, Ke
Zhao, Jing
Wang, Jingliang
Jiang, Fengxian
Xu, Wei
Yuan, Xiaotian
Lin, Xiaoyan
Fu, Guobin
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (05) : 2029 - 2039
[29] HER2 AND BRAF MUTATIONS IN NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS (P)
Estival, Anna
Carcereny, Enric
Indacochea, Alberto
Luis Ramirez, Jose
Moran, Teresa
Luis Cuadra, Jose
Vila, Laia
Gil, Maria
Botia, Monica
Perez, M.
Tierno, M.
Capdevila, Laia
Rosell, Rafael
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S957 - S957
[30] HER2 copy number variation in non-small cell lung cancer (NSCLC)
Tagliamento, M.
Auclin, E.
Valent, A.
Ferrara, R.
Cotteret, S.
Rouleau, E.
Caramella, C.
Melia, M. Riudavets
Gazzah, A.
Adam, J.
Jovelet, C.
Bayle, A.
Lacroix, L.
Auger, N.
Barlesi, F.
Planchard, D.
Besse, B.
Mezquita, L.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1050 - S1050

← 1 2 3 4 5 →